What is Celmatix?
Celmatix Inc. is a US-based biotechnology firm dedicated to advancing women's health through the development of novel therapeutics. The company's pipeline targets significant conditions such as endometriosis and Polycystic Ovary Syndrome (PCOS), leveraging cutting-edge research in female biology. Key initiatives include a first-in-class oral FSH receptor agonist designed to enhance fertility treatments, a JNK inhibitor for endometriosis management, and early-stage antibodies targeting AMH for ovarian folliculogenesis control. Celmatix's strategic focus on these areas positions it as a key player in transforming women's healthcare.
How much funding has Celmatix raised?
Celmatix has raised a total of $54.1M across 9 funding rounds:
Private Equity
$806K
Series A
$1.5M
Private Equity
$4M
Private Equity
$5.5M
Private Equity
$3.8M
Private Equity
$4.8M
Private Equity
$21M
Other Financing Round
$12.5M
Private Equity (2011): $806K, investors not publicly disclosed
Series A (2012): $1.5M supported by Topspin Partners
Private Equity (2013): $4M, investors not publicly disclosed
Private Equity (2014): $5.5M, investors not publicly disclosed
Private Equity (2015): $3.8M, investors not publicly disclosed
Private Equity (2016): $4.8M, investors not publicly disclosed
Private Equity (2016): $21M supported by Topspin Partners
Other Financing Round (2017): $12.5M featuring Topspin Partners
Key Investors in Celmatix
Topspin Partners
Topspin Partners is a private equity firm focused on growing branded consumer products and services companies. They provide capital and strategic guidance to help businesses scale and achieve long-term value.
What's next for Celmatix?
The substantial capital infusion into Celmatix signals a strong validation of its scientific approach and market potential. This financing is expected to accelerate the company's research and development efforts, potentially bringing its innovative therapies closer to clinical trials and market availability. The strategic backing will likely enable Celmatix to expand its operational capacity, further its drug discovery programs, and solidify its position in the competitive women's health sector. Continued investment in this space highlights a trend towards specialized biotech solutions addressing previously underserved patient populations.
See full Celmatix company page
